Literature DB >> 16985024

Endometrial cancer risk is associated with variants of the mismatch repair genes MLH1 and MSH2.

Mario E Beiner1, Barry Rosen, Anthony Fyles, Ian Harley, Tuya Pal, Kathy Siminovitch, Shiyu Zhang, Ping Sun, Steven A Narod.   

Abstract

Women with germ-line mutations in the mismatch repair genes (responsible for hereditary nonpolyposis colorectal cancer) face an increased risk of colonic and endometrial cancer. However, these germ-line mutations are rare and are responsible for fewer than 1% of endometrial cancers. Therefore, we examined whether or not common variants of the hereditary nonpolyposis colorectal cancer-associated genes might also be associated with an increased risk of endometrial cancer. Three single-nucleotide polymorphisms were selected in the MLH1 and MSH2 mismatch repair genes. All the various 672 women with endometrial cancer and 880 controls were genotyped. Each of these three single-nucleotide polymorphisms was associated with an increased risk of endometrial cancer. Carriers of the MLH1 nt-93 A allele were at a 1.5-fold increased risk of developing endometrial cancer compared with controls [95% confidence interval (95% CI), 1.2-2.0; P = 0.001]. The risk was higher for homozygote carriers [odds ratio (OR), 1.9; 95% CI, 1.2-3.2; P = 0.009]. For carriers of the MSH2 rs2303428 C allele, the OR was 1.4 (95% CI, 1.0-1.9; P = 0.05), and for carriers of the MSH2 rs2059520 G allele, the OR was 1.3 (95% CI, 1.0-1.7; P = 0.03). More than 9% of endometrial cancer cases carried a variant allele in both MLH1 and MSH2. For these women, the risk of endometrial cancer was particularly high (OR, 2.1; 95% CI, 1.2-3.6; P = 0.005). For patients younger than 50 years at diagnosis who carried both variants, the risk was even higher (OR, 3.4; 95% CI, 1.7-6.6; P = 0.0005). In summary, two common variant alleles of the MLH1 and MSH2 genes make a substantial contribution to endometrial cancer incidence in Ontario.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16985024     DOI: 10.1158/1055-9965.EPI-06-0257

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  18 in total

1.  Association between the hMSH2 IVS12-6 T>C polymorphism and cancer risk: A meta-analysis.

Authors:  Song Wu; Jingyu Chen; Yong Ji; Yuxin Liu; Lu Gao; Guoqiang Chen; Kai Shen; Bin Huang
Journal:  Exp Ther Med       Date:  2011-08-16       Impact factor: 2.447

2.  Effect of MLH1 -93G>A on gene expression in patients with colorectal cancer.

Authors:  Alexandre Funck; Juliana C Santos; Isabelle J L Silva-Fernandes; Silvia H B Rabenhorst; Carlos A R Martinez; Marcelo L Ribeiro
Journal:  Med Oncol       Date:  2014-08-13       Impact factor: 3.064

3.  ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.

Authors:  Daria Fleyshman; Peter Cheney; Anda Ströse; Shaila Mudambi; Alfiya Safina; Mairead Commane; Andrei Purmal; Kelsey Morgan; Nicholas J Wang; Joe Gray; Paul T Spellman; Natalia Issaeva; Katerina Gurova
Journal:  Cell Cycle       Date:  2015-12-22       Impact factor: 4.534

4.  A polymorphism within the mismatch repair gene predicts prognosis and adjuvant chemotherapy benefit in gastric cancer.

Authors:  Xiaohui Zhao; Dongfang Dai; Xiaoqin Li; Bo Shen; Xiaofeng Chen; Yongqian Shu; Deqiang Wang
Journal:  Gastric Cancer       Date:  2019-04-15       Impact factor: 7.370

Review 5.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

Authors:  M Christine Hollander; Gideon M Blumenthal; Phillip A Dennis
Journal:  Nat Rev Cancer       Date:  2011-04       Impact factor: 60.716

6.  Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico.

Authors:  Wilfredo E De Jesus-Monge; Carmen Gonzalez-Keelan; Ronghua Zhao; Stanley R Hamilton; Miguel Rodriguez-Bigas; Marcia Cruz-Correa
Journal:  Fam Cancer       Date:  2010-06       Impact factor: 2.375

7.  Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma.

Authors:  L J Worrillow; A G Smith; K Scott; M Andersson; A J Ashcroft; G M Dores; B Glimelius; E Holowaty; G H Jackson; G L Jones; C F Lynch; G Morgan; E Pukkala; D Scott; H H Storm; P R Taylor; M Vyberg; E Willett; L B Travis; J M Allan
Journal:  J Med Genet       Date:  2007-10-24       Impact factor: 6.318

8.  Specific variants in the MLH1 gene region may drive DNA methylation, loss of protein expression, and MSI-H colorectal cancer.

Authors:  Miralem Mrkonjic; Nicole M Roslin; Celia M Greenwood; Stavroula Raptis; Aaron Pollett; Peter W Laird; Vaijayanti V Pethe; Theodore Chiang; Darshana Daftary; Elizabeth Dicks; Stephen N Thibodeau; Steven Gallinger; Patrick S Parfrey; H Banfield Younghusband; John D Potter; Thomas J Hudson; John R McLaughlin; Roger C Green; Brent W Zanke; Polly A Newcomb; Andrew D Paterson; Bharati Bapat
Journal:  PLoS One       Date:  2010-10-13       Impact factor: 3.240

9.  Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Ken Kawamoto; Nobuyuki Kikuno; Yutaka Suehiro; Naoko Okayama; Yuichiro Tanaka; Rajvir Dahiya
Journal:  J Urol       Date:  2008-03-20       Impact factor: 7.450

10.  Ovarian cancer risk is associated with a common variant in the promoter sequence of the mismatch repair gene MLH1.

Authors:  Ian Harley; Barry Rosen; Harvey A Risch; Kathy Siminovitch; Mario E Beiner; John McLaughlin; Ping Sun; Steven A Narod
Journal:  Gynecol Oncol       Date:  2008-04-10       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.